Drugs / 89Zr-DFO-CZP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03546335 | Oct 2018 → Mar 2029 | rheumatoid arthritis | University of California, San Francisco | Suspended | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-CZP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03546335 ↗ |
| Known as | 89Zr-DFO-Certolizumab pegol | “89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent” NCT03546335 ↗ |
| Modality | Diagnostic / imaging agent | “is a radiopharmaceutical imaging agent” NCT03546335 ↗ |